Foreign institutional investors (FIIs) have reduced their stake in Biocon by 98 basis points to 13.05 percent at the end of September 2014 quarter from 14.03 percent as on June 30, 2014. On the flip side, domestic institutional investors (DIIs) have raised their shareholding in the bank by 92 basis points to 6.95 percent in Q2FY15 from 6.03 percent as on June 30, 2014.
Biocon is India’s largest and Asia's leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
